New Real-World Clinical Evidence Confirms ProFound AI Boosts Radiologists’ Efficiency and Accuracy

Company’s Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at ECR 2023

iCAD, a global medical technology leader providing innovative cancer detection and therapy solutions, announced new real-world clinical evidence to be presented at the European Congress of Radiology (ECR) 2023 meeting confirms ProFound AI boosts radiologists’ efficiency and accuracy. The Company is also showcasing its Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools in booth #AI-14 (Expo X1) at the meeting, which is taking place in Vienna from March 1-5.

AiThority Interview : AiThority Interview with João Graça, Co-founder and CTO at Unbabel

 “At ECR this year, we are pleased to again see physicians share their real-world clinical experience and evidence that iCAD’s AI Breast Suite has a positive impact on cancer detection and women’s lives. Our unique AI solutions are clinically proven to assist clinicians in daily practice to detect more cancers, evaluate breast density, and identify women at high risk of developing breast cancer in the short-term,” said Michele Debain, Senior Vice President and General Manager, Europe, Middle East, Africa, Asia Pacific.

“iCAD’s comprehensive suite of breast AI solutions offers clinically proven benefits to clinicians and patients alike,” said Stacey Stevens, President and CEO of iCAD, Inc. “A growing number of leading imaging facilities worldwide trust our technologies to detect cancer and stop it in its tracks – streamlining workflow, improving accuracy, and personalizing results like never before.”

In a research presentation session on Friday, March 3 from 16:00-17:30 CET, Kathy Schilling, MD, Medical Director, Christine E. Lynn Women’s Health & Wellness Institute, Boca Raton Regional Hospital, USA, will present findings from a study titled “Real-world breast cancer screening performance with digital breast tomosynthesis before and after implementation of an artificial intelligence detection system.” After comparing the performance of nine dedicated breast radiologists reading screening digital breast tomosynthesis (DBT) exams two years before and two years after adopting ProFound AI for DBT, researchers found ProFound AI helped radiologists find 1.31 more cancers per 1,000 screening exams for a 23% relative increase in cancer detection rate, without increasing the rate of recalls.

Read More Interview: AiThority Interview with Anthony Katsur, Chief Executive Officer at IAB Tech Lab

“After using ProFound AI for more than two years in daily practice, we have found not only marked improvements in efficiency and performance, but also tremendous improvements in cancer detection rates. This means we are finding more cancers and reading cases more accurately, without increasing the rate of false positives and unnecessary callbacks,” said Dr. Schilling. “ProFound AI also empowers our team to read cases faster and with more confidence. It’s like having another expert looking at the images right by your side.”

Studies demonstrating the clinical benefits of ProFound AI® for 2D Mammography and ProFound AI® Risk will also be presented at ECR. Initial results from these studies were recently highlighted at the Radiological Society of North America (RSNA) Annual Meeting in Chicago late last year.

 On Thursday, March 2, iCAD will also host an “AI After Dark” dinner and cocktail event, featuring renowned leaders in breast imaging AI who will discuss how iCAD’s Breast AI Suite has enhanced clinical practice and patient care at their facilities. Featured presenters include:

• Kathy Schilling, MD, Medical Director, Christine E. Lynn Women’s Health & Wellness Institute, Boca Raton Regional Hospital, Florida, USA
• Axel Gräwingholt, MD, Radiologie am Theater, Paderborn, Germany